Results: Analysis included 64 patients (median age 38, range 19-63) mainly men (81%). 49 (77%) patients had ALT activity > 40 U/l. Distribution of fibrosis: F0 (6%), F1 (50%), F2 (37%), F3 (7%), F4 (3%) and inflammatory activity: A0 (0%), A1 (19%), A2 (69%), A3 (9%) A4 (0%). The distribution of genotypes for marker rs1 2979860 was CC 40.6%, CT 45.3%, TT 14.1%, for rs8099917TT 59.4%, TG 32.8, GG 7.8% and for rs1 2980275 AA 39.1 %, AG 46.8%, GG 14.1 %. The presence of favorable

prognostic genotype was statistically significantly associated with decreased relative expression of genes IFI27, MX1 i ISG15 in liver specimens compared with patients with unfavorable genotypes for each marker analyzed (p<0,001). IP 10 gene was also find more observed for the reduction of favorable genotypes of the analyzed markers, however the differences were not statistically significant (p>0.05). Regardless of the analyzed markers the largest differences were observed in expression of gene IFI27. The comparative analysis showed that rs12979860 differentiates the most the expression of the analyzed genes. No effect of liver disease advancement was found on the observed relationship between genetic variation

and gene expression. Conclusions: A relationship was found between genotype markers SCH727965 supplier rs1 2979860, rs8099917, rs1 2980275 and the level of expression of ISG genes, such as IFI27, MX1 i ISG15. Patients with favorable IL-28B genotypes are characterized by a lower ISG genes expression. The effect of variation within IL-28B on the results of treatment may be associated with changes in ISG genes expression profiles induced by interferon. Disclosures: The following people have nothing to

disclose: Krzysztof Domagalski, Malgorzata Pawlowska, Andrzej Tretyn, Waldemar Halota Background: Antiviral treatment (AVT) for hepatitis C virus (HCV) infection reduces the risk of liver disease progression. However, the effect of AVT on progression of liver disease in HCV-infected cancer patients (pts) is unknown and management guidelines are lacking for this population. MCE公司 We aimed to study the effect of AVT on liver disease progression in HCV-infected pts with cancer. Methods: Records of HCV-infected pts with any type of cancer seen at MD Anderson Cancer Center (2008-2011) were reviewed retrospectively. Baseline characteristics were compared between pts who did or did not receive AVT. The probability of developing cirrhosis and portal hypertension (PH) was estimated by Kaplan-Meier curves. The statistical significance of the difference between treated vs. non-treated pts was determined by log-rank test. Multivariable Cox proportional hazards regression model was used to determine the association between AVT and liver disease progression. Results: Out of 642 HCV-infected cancer pts seen during the study period, 348 (54%) received AVT.